Analysis Finds That a Relatively Small
Number of Drugs Account for the Majority of Medicare Prescription Drug
Spending
A new KFF
analysis finds that a relatively small share of drugs, mainly
those without generic or biosimilar competitors, accounted for a
disproportionate share of prescription drug spending in Medicare in 2019.
This finding suggests that recent proposals that focus on prices for a
limited number of high-cost drugs could achieve significant savings.
The 250 top-selling
drugs in Medicare Part D with one manufacturer and no generic or
biosimilar competition – or roughly 7 percent of the more than 3,500 Part
D covered drugs -- accounted for 60 percent of the net total Part D
spending of $145 billion in 2019, the analysis finds. Part D is
Medicare’s voluntary benefit that covers retail prescription drugs for 46
million enrollees in 2020.
Similarly in Medicare
Part B, the top 50 covered drugs – or 8.5 percent of all Part B covered
drugs -- accounted for 80 percent of total Part B drug spending of $37
billion in 2019. Medicare Part B pays for prescription drugs administered
by physicians and other providers in outpatient settings for conditions
such as cancer and rheumatoid arthritis.
|
No comments:
Post a Comment